These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

123 related items for PubMed ID: 6784907

  • 1. Clinical trials with the hexitol derivatives in the U.S.
    Chiuten DF, Rozencweig M, Von Hoff DD, Muggia FM.
    Cancer; 1981 Feb 01; 47(3):442-51. PubMed ID: 6784907
    [Abstract] [Full Text] [Related]

  • 2. Toxicity, antitumour and haematological effects of 1,2-anhydro-6-bromogalactitol and d-mannitol: a comparison with the related dibromo- and dianhydro-derivatives.
    Horváth IP, Somfai-Relle S, Hegedüs L, Jarman M.
    Eur J Cancer Clin Oncol; 1982 Jun 01; 18(6):573-7. PubMed ID: 6811281
    [Abstract] [Full Text] [Related]

  • 3. Chemotherapeutic approaches to brain tumors. Experimental observations with dianhydrogalactitol and dibromodulcitol.
    Levin VA, Wheeler KT.
    Cancer Chemother Pharmacol; 1982 Jun 01; 8(1):125-31. PubMed ID: 7094198
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics and metabolism of dianhydrogalactitol DAG in patients: a comparison with the human disposition of dibromodulcitol DBD.
    Horváth IP, Csetényi J, Kerpel-Fronius S, Hegedüs L, Kanyár B, Eckhardt S.
    Eur J Cancer Clin Oncol; 1986 Feb 01; 22(2):163-71. PubMed ID: 3699079
    [Abstract] [Full Text] [Related]

  • 5. Complex evaluation of the effect of some cytostatic hexitol derivatives.
    Holczinger L, Somfai-Relle S, Institoris E, Gáti E, Turi G.
    Oncology; 1980 Feb 01; 37 Suppl 1():104-8. PubMed ID: 7454197
    [Abstract] [Full Text] [Related]

  • 6. Phase I and II studies of cytostatic hexitol derivatives: the role of alkylating metabolites?
    Eckhardt S, Kerpel-Fronius S, Horváth IP, Institoris L.
    Gan To Kagaku Ryoho; 1985 Mar 01; 12(3 Pt 2):783-8. PubMed ID: 3985644
    [No Abstract] [Full Text] [Related]

  • 7. A comparative study of dibromomannitol and busulfan in the treatment of chronic myeloid leukemia. A study of cancer and leukemia group B.
    Silver RT, Mick R, Cooper R, Ellison RR, Levy R, Brunner K, Schwartz JM, Holland JF.
    Cancer; 1987 Oct 01; 60(7):1442-8. PubMed ID: 3113712
    [Abstract] [Full Text] [Related]

  • 8. Metabolism and pharmacokinetics of dibromodulcitol (DBD, NSC-104800) in man--II. pharmacokinetics of DBD.
    Horváth IP, Csetényi J, Hindy I, Kerpel-Fronius S, Institoris I, Hegedüs I, Eckhardt S.
    Eur J Cancer Clin Oncol; 1982 Nov 01; 18(11):1211-9. PubMed ID: 6891658
    [Abstract] [Full Text] [Related]

  • 9. Mutagenicity of dibromodulcitol (DBD), an alkylating anticancer drug) and its mono- and bifunctional conversion products studied by the Salmonella/microsome assay.
    Tóth K, Sugár J, Somfai-Relle S, Hedegüs L.
    Carcinogenesis; 1982 Nov 01; 3(3):333-6. PubMed ID: 7044598
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics of dibromodulcitol in humans: a phase I study.
    Kelley SL, Peters WP, Andersen J, Furlong EA, Frei E, Henner WD.
    J Clin Oncol; 1986 May 01; 4(5):753-61. PubMed ID: 3517245
    [Abstract] [Full Text] [Related]

  • 11. Interaction of GGCC sequences of DNA with anticancer dianhydrogalacticol, detected by inhibition of restriction enzyme BspI.
    Financsek I, Guczi J, Hidvégi EJ.
    Acta Biochim Biophys Acad Sci Hung; 1984 May 01; 19(3-4):177-84. PubMed ID: 6100663
    [Abstract] [Full Text] [Related]

  • 12. Hungarian anticancer drugs (antineoplastics).
    Kerpel-Fronius S.
    Ther Hung; 1982 May 01; 30(3):110-21. PubMed ID: 6095482
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Rat liver-mediated degradation of dibromodulcitol.
    Csetényi J, Gáti E, Hegedüs L, Horváth IP, Holczinger L.
    Eur J Cancer Clin Oncol; 1985 Jul 01; 21(7):881-5. PubMed ID: 4043174
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Dominance of resistance to the alkylating agent 1,2:5,6-dianhydrogalactitol in P388 mouse lymphoma hybrid cells.
    Pályi I, Bence J, Szikla K, Hullán L.
    Cancer Chemother Pharmacol; 1989 Jul 01; 23(1):41-6. PubMed ID: 2909289
    [Abstract] [Full Text] [Related]

  • 18. Use of 1,2:5,6-dianhydrogalactitol in studies on cell kinetics-directed chemotherapy schedules in human tumors in vivo.
    Barranco SC, Townsend CM, Costanzi JJ, May JT, Baltz R, O'Quinn AG, Leipzig B, Hokanson KM, Guseman LF, Boerwinkle WR.
    Cancer Res; 1982 Jul 01; 42(7):2899-2905. PubMed ID: 7083178
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Incorporation of 3H-dibromodulcitol and 3H-dianhydrodulcitol into ascites tumor cells. Autoradiographic study.
    Kopper L, Lapis K, Institóris L.
    Neoplasma; 1976 Jul 01; 23(1):47-52. PubMed ID: 1272473
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.